about
Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically activeNephrectomized and hepatectomized animal models as tools in preclinical pharmacokineticsMechanistic and functional differentiation of tapentadol and tramadolPharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesLong-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicityToward a systematic approach to opioid rotation.Codeine-induced hyperalgesia and allodynia: investigating the role of glial activationThe efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.Analytic reviews: managing the agitated patient in the ICU: sedation, analgesia, and neuromuscular blockade.Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes.A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.Topical review on the abuse and misuse potential of tramadol and tilidine in Germany.Pharmacogenomics of methadone maintenance treatment.Relationships between plasma concentrations of morphine, morphine-3-glucuronide, morphine-6-glucuronide, and intravenous morphine titration outcomes in the postoperative period.The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients.Mapping of endogenous morphine-like compounds in the adult mouse brain: Evidence of their localization in astrocytes and GABAergic cells.Is maternal opioid use hazardous to breast-fed infants?European Pain Federation position paper on appropriate opioid use in chronic pain management.CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study.Urinary hydrocodone and metabolite distributions in pain patients.Hair analysis for opiates: hydromorphone and hydrocodone as indicators of heroin use.
P2860
Q24629014-820BA22B-07F2-4DE5-BFF2-5F2D91869E1CQ27027552-C175F70C-5110-440B-A064-62D25BDD97ACQ28268772-13DB64B1-1DA4-4C38-BCB0-BC1D31F1F47FQ33726256-C3BD390F-F919-4BEC-B270-0863D4DBCF4BQ34272502-99C28E33-A64E-4434-A7B2-71C47E9F2FD0Q34285100-A4B73856-5B1A-4008-9C5E-A824DEC4EF29Q34394425-F36145AF-0919-45B9-850C-32083E26ED85Q34658014-058DBBA3-9733-4475-9DB9-CEFB9FDCF11CQ34948237-8DD5E8AD-5DFE-4D24-877F-1D17F00ED203Q34965527-B8322F25-AD31-4C21-A082-9ECCDBF965A8Q36111225-97EB4B2B-4E0F-4B2B-988C-B647A464AA9BQ36390262-4AA7A9D5-08EB-4D7D-858F-18A0FA950B27Q37776069-2648CDA4-635F-4131-9B56-C4F6B31F6902Q37810229-1111A5C4-DACC-46EB-9635-3B155930EE9BQ37895002-0CF43D5A-FFD2-41E0-BF02-05594BDF14CCQ38120828-68A224F6-71C9-468C-A06F-414332BE3420Q38222510-64BF18E6-CD1C-4FC8-89D8-9D013E00090EQ39280262-840FCC7D-4D79-4A8C-B2FD-2C7EC123BBCCQ40449086-B0AAF398-F2EE-4529-8725-2502AC832173Q42486161-B46D6D87-3AFA-40DC-A178-721E19A3A359Q43063862-45D9B628-36A1-4EFF-A2C4-11287A9A427DQ44342097-F77EB842-5048-4200-A2C4-4716153988CBQ44345641-CFE0D6CD-3993-4291-A770-B94191C28D96Q46065047-1088A6DE-5BD6-4DB2-B323-197DEBF4F9E9Q53775561-FE89A53A-04BD-4E90-AA65-560EC338105E
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Role of active metabolites in the use of opioids
@ast
Role of active metabolites in the use of opioids
@en
Role of active metabolites in the use of opioids
@nl
type
label
Role of active metabolites in the use of opioids
@ast
Role of active metabolites in the use of opioids
@en
Role of active metabolites in the use of opioids
@nl
prefLabel
Role of active metabolites in the use of opioids
@ast
Role of active metabolites in the use of opioids
@en
Role of active metabolites in the use of opioids
@nl
P2860
P1476
Role of active metabolites in the use of opioids
@en
P2093
Andrew A Somogyi
Janet K Coller
P2860
P2888
P304
P356
10.1007/S00228-008-0570-Y
P407
P577
2009-02-01T00:00:00Z
P5875
P6179
1000713367